Humana Inc. (NYSE:HUM) Short Interest Update

Humana Inc. (NYSE:HUM) saw a large increase in short interest in March. As of March 31st, there was short interest totaling 5,937,118 shares, an increase of 19.3% from the March 15th total of 4,977,893 shares. Based on an average daily trading volume, of 1,708,634 shares, the days-to-cover ratio is currently 3.5 days. Currently, 5.0% of the shares of the stock are sold short.

Humana Price Performance

Shares of Humana stock traded up $4.33 during mid-day trading on Friday, reaching $205.09. 1,895,625 shares of the stock were exchanged, compared to its average volume of 1,765,477. The company has a market cap of $24.62 billion, a price-to-earnings ratio of 20.89, a price-to-earnings-growth ratio of 2.15 and a beta of 0.44. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70. The firm has a 50-day simple moving average of $181.32 and a 200 day simple moving average of $230.97. Humana has a fifty-two week low of $163.11 and a fifty-two week high of $315.35.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The business had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the company posted ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, sell-side analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.7%. Humana’s dividend payout ratio (DPR) is 36.05%.

Insider Activity

In other Humana news, insider Sanjay K. Shetty acquired 810 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was bought at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the purchase, the insider owned 11,657 shares in the company, valued at $2,158,992.97. This represents a 7.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Humana

A number of hedge funds have recently made changes to their positions in the company. Illinois Municipal Retirement Fund increased its position in Humana by 9.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 49,658 shares of the insurance provider’s stock valued at $12,920,000 after acquiring an additional 4,351 shares in the last quarter. Bank of New York Mellon Corp increased its position in Humana by 161.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider’s stock valued at $446,911,000 after acquiring an additional 1,060,767 shares in the last quarter. National Pension Service increased its position in Humana by 2.8% in the 3rd quarter. National Pension Service now owns 189,601 shares of the insurance provider’s stock valued at $49,328,000 after acquiring an additional 5,150 shares in the last quarter. Long Focus Capital Management LLC acquired a new stake in Humana in the 3rd quarter valued at about $34,212,000. Finally, Tejara Capital Ltd acquired a new stake in Humana in the 3rd quarter valued at about $1,873,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group dropped their price objective on shares of Humana from $215.00 to $158.00 and set a “sell” rating for the company in a research note on Friday, February 13th. Morgan Stanley set a $146.00 price objective on shares of Humana in a research note on Thursday, February 12th. Leerink Partners dropped their price objective on shares of Humana from $267.00 to $185.00 and set a “market perform” rating for the company in a research note on Thursday, February 12th. Robert W. Baird dropped their price objective on shares of Humana from $264.00 to $205.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Barclays dropped their price objective on shares of Humana from $245.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Seven investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $222.09.

Key Headlines Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana secured a $30 million settlement from Lupin’s U.S. unit over an antitrust claim, a cash recovery that removes litigation uncertainty and modestly improves near-term cash/earnings visibility. Article Title
• Positive Sentiment: Humana announced a quarterly dividend of $0.885 per share (record June 26, paid July 31), which supports yield-focused investors and signals board confidence in cash generation. Dividend Announcement
• Neutral Sentiment: Jim Cramer discussed Humana’s business on CNBC/linked coverage, increasing retail investor attention — media mentions can boost trading volume and momentum but don’t change fundamentals by themselves. Article Title
• Negative Sentiment: Zacks Research sharply downgraded Humana from “Hold” to “Strong Sell” and trimmed multiple near- and multi‑year EPS estimates (Q1 2026, FY2026–FY2028 and several 2027 quarters). The downgrade and the handful of small estimate cuts increase selling pressure and signal analyst concerns about near-term profitability. Zacks Research
• Negative Sentiment: Humana disclosed a data breach affecting customers in Texas and five other states — this raises potential customer, regulatory and remediation costs and could create reputational headwinds. Data Breach Article

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.